Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pumitamig versus durvalumab after concurrent chemoradiation in unresectable stage III NSCLC
NL-OMON61175Phase 3Not yet recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jun 2026
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of pumitamig, durvalumab in non-small cell lung cancer (NSCLC), sponsored by Bristol Myers Squibb. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
pumitamigdurvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON61175.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61175.